Uppsala, Sweden – August 10, 2020 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces it has received a “paragraph IV” patent certification notice from Sun Pharmaceutical Industries Limited (“Sun”). The Notice Letter advises Orexo of Sun’s filing of an Abbreviated New Drug ... read more

Oslo, Norway, 10 August 2020 Nordic Nanovector ASA (OSE: NANO) announces that Dr Christine Wilkinson Blanc has been appointed Chief Medical Officer with immediate effect. Dr Wilkinson Blanc is a seasoned pharmaceutical physician with broad experience in oncology and haematology with bot... read more

STOCKHOLM — August 7, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) announced today that the first patient has been enrolled in the Immunoglobulin Light Chain (AL) amyloidosis (OP-201) study. This open-label, phase 1/2 study of melflufen and dexamethasone for patients with AL ... read more

Oslo, Norway, 6 August 2020 Nordic Nanovector ASA (OSE: NANO) today announces that, following a planned interim analysis of the PARADIGME Phase 2b pivotal trial of Betalutin® in patients with relapsed/refractory follicular lymphoma (FL), the Independent Review Committee (IRC) has reco... read more

HAMILTON, Ontario and BOSTON, Aug. 5, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that Chief Executive Officer John Valliant, Ph.D., will... read more